press releases

Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints Novocure plans to submit a Humanitarian Device Exemption application to the FDA for approval ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today positive top-line results from its STELLAR phase 2… Read More

Data support utility of Tumor Treating Fields in a variety of solid tumors A total of 35 presentations on the application of Tumor Treating Fields in seven cancer types will be presented ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that new data on… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2018 on Thursday, April 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months… Read More

Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in… Read More

The clinical and preclinical research to be presented includes the application of Tumor Treating Fields in seven cancer types ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14… Read More

1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016, and an increase of 9 percent versus September 30, 2017 Delivered record quarterly net revenues of $53.7 million, representing 77 percent growth versus December 31, 2016, and 7 percent growth versus… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has entered into a $150 million term loan agreement with BioPharma Credit PLC (LSE: BPCR), an investment fund managed by Pharmakon Advisors, LP, with proceeds used to pay in full Novocure’s existing $100 million term loan debt and… Read More

Health-related quality of life was maintained for a longer period of time in several predefined health scales in EF-14 trial patients treated with a combination of Optune and temozolomide compared to patients treated with temozolomide alone The use of Optune together with temozolomide extended progression free and… Read More

1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016 Fourth quarter 2017 preliminary net revenues of $53.7 million, reflecting 77 percent growth versus fourth quarter 2016 Fourth quarter and full year 2017 financial results to be reported Thursday,… Read More